Haloxyl 10 mg is an oral fluoxymesterone tablet manufactured by Kalpa Pharmaceuticals and dosed at 10 mg per tablet, supplied in packs of 50 tablets.
Haloxyl 10 mg contains fluoxymesterone, a potent 17-alpha-alkylated oral anabolic-androgenic steroid first approved by the FDA in 1956. Fluoxymesterone is known for its strong androgenic activity and is commonly referenced in non-medical bodybuilding contexts for its effects on strength and hardness rather than significant mass gains.
In clinical practice, fluoxymesterone is used for the treatment of hypogonadism in males and for palliative therapy in certain cases of breast cancer in women. In bodybuilding and performance-enhancement settings, it is often used during pre-contest phases or strength-focused cycles, though such use falls outside approved medical indications.
Fluoxymesterone supports increased protein synthesis and nitrogen retention, contributing to strength and muscle hardness. As a 17-alpha-alkylated compound, it is associated with hepatotoxicity and requires cautious use and monitoring in any context.
Haloxyl 10 mg is supplied as an oral compressed tablet containing 10 mg of fluoxymesterone per unit, packaged in a 50-tablet format by Kalpa Pharmaceuticals.
Fluoxymesterone is a potent oral anabolic steroid characterized by strong androgenic activity, oral bioavailability, and a relatively long half-life. Its profile differs from injectable compounds and other oral anabolics.
Fluoxymesterone is a 17-alpha-alkylated compound, which allows it to survive first-pass metabolism in the liver and remain orally active. This structural modification is also responsible for its classification as a hepatotoxic compound, requiring periodic liver function monitoring during any use.
The compound has strong androgenic effects, promoting increased protein synthesis and nitrogen retention. Unlike some oral anabolics, fluoxymesterone is not aromatized to estrogen, which means estrogenic side effects such as gynecomastia are less commonly associated with its use compared to aromatizable compounds.
Fluoxymesterone is regulated as a Schedule III controlled substance in the United States. Its use in athletics is prohibited by major anti-doping organizations.
Fluoxymesterone has an elimination half-life of approximately 9.2 hours, which is longer than many other oral anabolic steroids. This allows for less frequent administration compared to compounds with shorter half-lives.
Kalpa Pharmaceuticals offers several oral anabolic preparations with different compounds, potencies, and intended profiles. The main distinctions involve hepatotoxicity, aromatization potential, and anabolic-to-androgenic ratios.
For those comparing oral options, Dianoxyl 10 (methandienone) is a potent oral anabolic commonly referenced for bulking, though it is aromatizable and associated with water retention. Anadroxyl (oxymetholone) is another potent oral for mass gain but is generally considered more hepatotoxic. For cutting or leaner gains, Stanoxyl 10 (stanozolol) is a non-aromatizing oral alternative, though it is also 17-alpha-alkylated.
The information below is provided for educational reference only. Fluoxymesterone is a Schedule III controlled substance in the United States; medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring. Non-medical use falls outside approved indications.
In medically supervised settings, fluoxymesterone dosing for hypogonadism in males ranges from 5 to 20 mg per day, while palliative therapy for breast cancer in women uses 10 to 40 mg per day in divided doses. In non-medical bodybuilding contexts, fluoxymesterone is commonly referenced in the range of 10–40 mg per day, though such use falls outside approved medical indications and carries significant hepatotoxic risk.
| Use Case | Common Reference Range | Frequency |
|---|---|---|
| Medical (male hypogonadism) | 5–20 mg per day | Once daily or divided |
| Medical (breast carcinoma) | 10–40 mg per day | Divided doses (3–4x daily) |
| Bodybuilding (non-medical) | 10–40 mg per day | Divided doses |
| Pre-contest (non-medical reference) | 20–30 mg per day | Divided doses |
In non-medical bodybuilding contexts, fluoxymesterone is commonly used during pre-contest phases or strength-focused cycles, often stacked with injectable compounds. It is not typically used as a mass-building compound due to its strong androgenic profile and limited anabolic effects compared to other orals.
Cycle duration in non-medical use is typically limited to 4–6 weeks due to the compound's 17-alpha-alkylated structure and associated liver stress. Bloodwork and liver function monitoring are strongly advised if any use occurs.
Fluoxymesterone is associated with significant side effects including hepatotoxicity, elevated blood pressure, and androgenic effects such as acne and aggression. Aromatase inhibitors such as Arimixyl 1 mg (anastrozole) are generally not relevant for fluoxymesterone since it does not aromatize, but may be referenced in stacked cycles involving aromatizable compounds.
Blood pressure, liver enzymes, and hematocrit should be monitored during any use. Cardiovascular and hepatic risks are significant at supraphysiologic doses.
After any non-medical cycle involving fluoxymesterone, post-cycle therapy is commonly recommended to support recovery of endogenous testosterone production. Selective estrogen receptor modulators such as Clomixyl 50 mg (clomiphene) or Nolvaxyl 20 mg (tamoxifen) are commonly referenced for this purpose in bodybuilding contexts.
PCT protocols vary based on cycle length, compounds used, and individual response. Bloodwork can help inform recovery strategy.
Dosing strategies and support protocols should be adjusted based on experience level, health status, and bloodwork where possible. The information above is for educational reference and does not constitute medical advice.
Fluoxymesterone is a controlled anabolic steroid with significant hepatic, cardiovascular, and endocrine effects. Medical use requires appropriate diagnosis, clinical supervision, and ongoing monitoring.
Fluoxymesterone has not been shown to be safe and effective for the enhancement of athletic performance, and because of the potential risk of serious adverse health effects, it should not be used for such purpose. It is regulated as a Schedule III controlled substance in the United States.
Non-medical use of fluoxymesterone at supraphysiologic doses falls outside approved indications and can substantially increase exposure to hepatotoxic, cardiovascular, and androgenic adverse effects.
Fluoxymesterone is a Schedule III controlled substance in the United States. Non-medical use is associated with serious health risks, including liver injury, cardiovascular events, and hormonal suppression.
Hepatotoxicity is a primary concern with fluoxymesterone. As a 17-alpha-alkylated compound, it is associated with elevated liver enzymes, cholestatic jaundice, and other hepatic complications. Liver function tests should be monitored periodically during any use.
Cardiovascular effects include decreased HDL cholesterol, increased LDL cholesterol, and elevated blood pressure. These changes are associated with increased atherosclerosis risk.
Androgenic effects may include acne, oily skin, aggression, and suppression of endogenous testosterone production. In males, prolonged use can lead to oligospermia and testicular atrophy.
Fluoxymesterone administration has been shown to profoundly suppress plasma testosterone levels within 24 hours of beginning treatment.
Fluoxymesterone is contraindicated in men with known or suspected prostate or breast cancer, in women who are or may become pregnant, and in patients with severe hepatic dysfunction.
Pre-existing cardiovascular disease, liver disease, diabetes, and prostate conditions require careful evaluation before any consideration of fluoxymesterone use. Women should be monitored for signs of virilization, including voice deepening and clitoral enlargement, which may not be reversible.
Medically supervised fluoxymesterone therapy typically involves periodic liver function tests, hemoglobin and hematocrit monitoring for polycythemia, serum lipid evaluation, and assessment of hormonal status. Blood pressure and glucose tolerance should also be monitored.
Any use of fluoxymesterone should be accompanied by appropriate monitoring and medical supervision where possible.
Store in a cool, dry place away from direct light and moisture. Keep tablets in the original packaging until use. Keep out of reach of children.
Haloxyl 10 mg is supplied through the official Kalpa Pharmaceuticals distribution chain and shipped in original manufacturer packaging with discreet, privacy-focused handling.
The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details. Products are supplied through the official Kalpa Pharmaceuticals distribution chain.
To verify your Haloxyl 10 mg product, use the security code on the packaging and cross-check it on the Kalpa official site. Original Kalpa Pharmaceuticals presentation and packaging help reinforce product legitimacy and buyer confidence.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Proper storage conditions help preserve tablet integrity and stability throughout shelf life.
Store Haloxyl 10 mg in a cool, dry place away from excessive heat, moisture, and direct light. Maintaining stable conditions helps preserve the integrity of the tablets.
Keep the tablets in their original packaging until use. Do not use if the packaging is damaged or if the tablets appear abnormal in color or texture.
Keep out of reach of children. Follow proper handling practices for oral medications.
Answers to common questions about Haloxyl 10 mg, fluoxymesterone, dosing, side effects, and product specifications.
Haloxyl 10 mg contains fluoxymesterone, which is FDA-approved for treating hypogonadism in males and for palliative therapy in certain cases of breast cancer in women. In non-medical bodybuilding contexts, fluoxymesterone is commonly referenced for strength and hardness during pre-contest phases, though such use falls outside approved medical indications.
For medical use, fluoxymesterone is typically administered in divided doses three to four times daily to maintain stable blood levels due to its short action. In non-medical bodybuilding contexts, similar divided dosing schedules are commonly referenced.
Fluoxymesterone suppresses endogenous testosterone production, with studies showing profound suppression of plasma testosterone levels within 24 hours of beginning treatment. In non-medical bodybuilding contexts, post-cycle therapy is commonly recommended after any cycle involving this compound. Agents such as Clomixyl 50 mg or Nolvaxyl 20 mg are commonly referenced for this purpose.
Fluoxymesterone is an anabolic steroid that binds to androgen receptors, triggering increased protein synthesis and nitrogen retention in muscle tissues. It also stimulates erythropoiesis, the production of red blood cells, which can enhance oxygen delivery to muscles. Non-medical use for bodybuilding falls outside approved indications.
In medical settings, fluoxymesterone's effects on testosterone suppression can be observed within 24 hours of administration. In non-medical bodybuilding contexts, users often report noticeable strength and hardness effects within the first one to two weeks, though individual response varies.
There is no single oral steroid that is universally best. Fluoxymesterone is among the most androgenic oral anabolics, making it more suited to strength and hardness goals than mass gain. Other orals such as Dianoxyl 10, Anadroxyl, and Stanoxyl 10 have different potency, side effect, and aromatization profiles.
Both fluoxymesterone and oxymetholone are potent 17-alpha-alkylated oral anabolic steroids. Fluoxymesterone has a stronger androgenic profile and is more commonly referenced for strength and hardness, while oxymetholone is primarily used for mass gain but is generally considered more hepatotoxic.
Fluoxymesterone and stanozolol are both oral 17-alpha-alkylated anabolic steroids that do not aromatize. However, fluoxymesterone has a more androgenic profile and is associated with stronger androgenic side effects, while stanozolol is more commonly referenced for lean, dry gains with fewer androgenic effects.
In medical settings, fluoxymesterone dosing for hypogonadism ranges from 5 to 20 mg per day, with 10 mg representing the middle of the studied range. In non-medical bodybuilding contexts, 10 mg per day would be considered a low dose, with common reference ranges extending to 40 mg per day. Even at lower doses, fluoxymesterone carries hepatotoxic risk.
Haloxyl 10 mg is labeled at 10 mg of fluoxymesterone per tablet. It is supplied in packs of 50 tablets, giving 500 mg of total labeled fluoxymesterone content per pack.
Yes, fluoxymesterone and its metabolites are detectable in urine drug tests. Analytical methods using liquid chromatography-tandem mass spectrometry and gas chromatography-mass spectrometry can identify multiple fluoxymesterone metabolites in doping control samples.
Laboratory testing information for Haloxyl 10 mg is not currently available in this product listing. Kalpa Pharmaceuticals products are manufactured under pharmaceutical-grade conditions, but independent lab reports are not published for this specific product at this time.